NCT01506973View on ClinicalTrials.gov

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Advanced AdenocarcinomaMetastatic Adenocarcinoma
Interventions
DRUG

Hydroxychloroquine (HCQ)

no other names

DRUG

Gemcitabine

no other names

DRUG

Abraxane

no other names

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01506973 - A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer | Biotech Hunter | Biotech Hunter